HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hisataka Moriwaki Selected Research

VAP-cyclo protocol

1/2014Serum soluble tumor necrosis factor receptor 1 level is associated with the outcome of diffuse large B-cell lymphoma patients treated with the CHOP or R-CHOP regimen.
10/2013Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen.
5/2012Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens.
2/2004Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study.
11/2002[Nasal NK cell lymphoma with hemophagocytic syndrome developed tumor lysis syndrome after CHOP therapy].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Hisataka Moriwaki Research Topics

Disease

80Neoplasms (Cancer)
01/2018 - 09/2002
56Hepatocellular Carcinoma (Hepatoma)
10/2019 - 02/2002
51Carcinogenesis
01/2017 - 09/2002
41Liver Cirrhosis (Hepatic Cirrhosis)
10/2019 - 09/2003
30Inflammation (Inflammations)
01/2017 - 11/2004
22Obesity
03/2016 - 07/2006
19Pancreatic Neoplasms (Pancreatic Cancer)
08/2019 - 01/2009
19Colonic Neoplasms (Colon Cancer)
08/2018 - 01/2005
17Liver Diseases (Liver Disease)
01/2019 - 01/2002
16Fibrosis (Cirrhosis)
05/2018 - 07/2005
15Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
09/2017 - 06/2005
14Body Weight (Weight, Body)
05/2015 - 01/2005
13Colorectal Neoplasms (Colorectal Cancer)
07/2014 - 01/2004
11Liver Neoplasms (Liver Cancer)
01/2018 - 07/2006
11Malnutrition (Nutritional Deficiencies)
07/2014 - 01/2004
10Hepatitis
03/2016 - 11/2002
10Non-Hodgkin Lymphoma (Lymphosarcoma)
09/2015 - 06/2002
10Insulin Resistance
01/2015 - 05/2009
9Lymphoma (Lymphomas)
10/2018 - 11/2002
9Infections
03/2016 - 01/2006
7Ascites
01/2019 - 12/2011
7Neoplasm Metastasis (Metastasis)
01/2018 - 03/2011
7Adenoma (Adenomas)
03/2016 - 09/2002
6Hypoalbuminemia
05/2018 - 04/2004
6Hepatic Encephalopathy
05/2018 - 05/2010
6Aberrant Crypt Foci
12/2014 - 09/2008
6Leukemia
07/2013 - 05/2004
6Chronic Hepatitis C
03/2013 - 12/2005
5Hepatitis C
07/2016 - 01/2006
5Non-alcoholic Fatty Liver Disease
05/2016 - 10/2011
5Liver Failure
07/2014 - 01/2002
5Carcinoma (Carcinomatosis)
08/2013 - 06/2003
5Ulcer
11/2012 - 01/2002
4Fatty Liver
01/2017 - 01/2011
4Diabetes Mellitus
03/2016 - 07/2006
4Adenocarcinoma
02/2016 - 09/2002
4Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2016 - 08/2007

Drug/Important Bio-Agent (IBA)

39Proteins (Proteins, Gene)FDA Link
08/2019 - 09/2002
263,7,11,15- tetramethyl- 2,4,6,10,14- hexadecapentaenoic acidIBA
01/2018 - 05/2002
21Branched-Chain Amino AcidsIBA
05/2018 - 09/2003
17Prednisolone (Predate)FDA LinkGeneric
12/2017 - 01/2002
17Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
03/2013 - 01/2002
16TeaIBA
03/2015 - 01/2005
15Serum AlbuminIBA
10/2019 - 01/2004
15Green Fluorescent ProteinsIBA
10/2018 - 01/2012
14Red Fluorescent ProteinIBA
08/2019 - 01/2012
14Cyclophosphamide (Cytoxan)FDA LinkGeneric
12/2017 - 06/2002
13Vincristine (Oncovin)FDA LinkGeneric
12/2017 - 06/2002
13RetinoidsIBA
01/2014 - 11/2002
12Diethylnitrosamine (N-Nitrosodiethylamine)IBA
05/2016 - 08/2004
12Pharmaceutical PreparationsIBA
03/2016 - 01/2009
12InterferonsIBA
03/2013 - 05/2004
12ErbB Receptors (EGF Receptor)IBA
12/2011 - 04/2005
11Rituximab (Mabthera)FDA Link
09/2017 - 10/2006
11Messenger RNA (mRNA)IBA
03/2016 - 05/2002
11Retinoid X Receptors (Retinoid X Receptor)IBA
01/2014 - 02/2002
10Doxorubicin (Adriamycin)FDA LinkGeneric
12/2017 - 02/2004
10Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA
01/2016 - 02/2009
10Phosphotransferases (Kinase)IBA
03/2015 - 01/2004
10CytokinesIBA
08/2014 - 01/2002
9AdipokinesIBA
03/2016 - 07/2010
9AzoxymethaneIBA
02/2016 - 09/2002
8epigallocatechin gallate (epigallocatechin-3-gallate)IBA
09/2012 - 04/2005
7KynurenineIBA
12/2017 - 04/2010
7Drinking WaterIBA
02/2016 - 06/2004
7tyrosine receptor (receptor, tyrosine)IBA
03/2015 - 06/2008
7Epidermal Growth Factor (EGF)IBA
07/2011 - 04/2005
6pirarubicinIBA
12/2017 - 02/2004
6Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA
01/2014 - 03/2005
6LigandsIBA
10/2012 - 02/2002
6Insulin-Like PeptidesIBA
03/2011 - 04/2008
6beta CateninIBA
07/2010 - 09/2002
6Retinoid X Receptor alphaIBA
11/2009 - 02/2002
5Amino AcidsFDA Link
12/2017 - 01/2004
5Etoposide (VP 16)FDA LinkGeneric
09/2017 - 06/2002
5Ribavirin (Virazole)FDA LinkGeneric
07/2016 - 12/2005
5AlbuminsIBA
07/2016 - 04/2004
5GemcitabineFDA Link
03/2016 - 01/2009
5Antineoplastic Agents (Antineoplastics)IBA
03/2016 - 05/2004
5Tryptophan (L-Tryptophan)FDA Link
01/2016 - 10/2011
5Insulin (Novolin)FDA Link
01/2015 - 09/2005
5CateninsIBA
12/2014 - 06/2011
5Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA
10/2012 - 02/2002
5AntigensIBA
01/2010 - 06/2005
5Vitamin A (Retinol)FDA LinkGeneric
03/2009 - 04/2004
5NF-kappa B (NF-kB)IBA
06/2008 - 11/2004
4DiureticsIBA
05/2018 - 05/2014
4Cyclin D1IBA
03/2016 - 03/2010
4sodium sulfate (sodium bisulfate)FDA LinkGeneric
02/2016 - 03/2010
4Dextrans (Dextran)FDA Link
02/2016 - 03/2010
4EnzymesIBA
01/2016 - 05/2011

Therapy/Procedure

50Therapeutics
01/2018 - 06/2002
39Chemoprevention
03/2016 - 04/2004
22Drug Therapy (Chemotherapy)
01/2018 - 06/2002
6Intraperitoneal Injections
01/2016 - 08/2004
6Subcutaneous Injections
05/2015 - 07/2010
5Cell Transplantation
12/2017 - 11/2008
5VAP-cyclo protocol
01/2014 - 11/2002
5Aftercare (After-Treatment)
03/2013 - 09/2002
5Oral Administration
09/2010 - 08/2002